The EUR 46.50 cash offer represents a substantial premium; traders should monitor the spread to the offer price as a proxy for deal completion risk. Key catalysts include regulatory filings (antitrust, CFIUS) due within 20 business days, the EGM vote, and the 10-week acceptance period. The deal is financed with committed equity and debt, reducing financing risk, but regulatory and shareholder approval conditions create execution uncertainty.
Price Chart
Executive Summary
QIAGEN N.V. announced a definitive agreement to be acquired by Crown NL Bidco B.V., an EQT-backed entity, via a public tender offer at EUR 46.50 per share in cash, valuing the equity at approximately EUR 9.6 billion based on 206.5M outstanding shares. The transaction is structured as a tender offer followed by a demerger and share sale to take the company private, with unanimous board support and committed financing of EUR 5,966.9 million in equity plus debt. The offer represents a significant premium to the pre-announcement trading price, but completion is subject to regulatory approvals, shareholder votes, and a 50%+1 minimum tender condition.
Key Facts
- Offer price of EUR 46.50 per share in cash, all-cash consideration
- Equity financing of EUR 5,966.9 million committed via binding equity commitment letters
- Minimum acceptance threshold of 50%+1 of outstanding shares
- Unanimous board recommendation; fairness opinions from Moelis, Goldman Sachs, and Perella Weinberg
- Post-closing restructuring includes demerger, share sale, and potential delisting from NYSE and Frankfurt Stock Exchange
- Termination fee of EUR 150 million payable by QIAGEN in certain scenarios; reverse termination fee of EUR 300 million payable by Buyer for regulatory failure
- Offer subject to regulatory clearances (antitrust, CFIUS, investment screening) and shareholder approval at an EGM
- Long stop date of 15 months from signing (October 21, 2026)
Financial Impact
EUR 46.50 per share in cash; total equity value approximately EUR 9.6 billion based on 206,496,521 outstanding shares
Risk Factors
- Regulatory delays or failure to obtain antitrust/CFIUS clearances
- Shareholder vote may not achieve required majority, especially if less than 80% approval triggers board discretion
- Market conditions clause allows Buyer to walk if DAX or S&P 500 fall >25% from October 20, 2026 levels
- Potential competing superior proposal could trigger termination fee and derail deal
- Currency risk: offer in EUR but QIAGEN reports in USD; EUR/USD fluctuations affect perceived value for USD-based holders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0000950103-26-016060 |
| Document: dp255417_6k.htm | 0000950103-26-016060 |
| Document: 0000950103-26-016060-index-headers.html | 0000950103-26-016060 |
| Document: 0000950103-26-016060-index.html | 0000950103-26-016060 |
| Document: 0000950103-26-016060.txt | 0000950103-26-016060 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 5d ago | 6-K | $50.39 $50.37 | ▼ −0.04% | ▼ −0.75% | $50.17 (−0.44%) |
Oct 22, 2026 5d ago | SC TO-C | $50.22 $50.39 | ▲ +0.34% | ▲ +0.86% | $50.17 (−0.10%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers